Showing 7371-7380 of 8649 results for "".
- Genentech Presents Longer-Term Efficacy and Safety for Enspryng in NMOSDhttps://modernod.com/news/genentech-presents-longer-term-efficacy-and-safety-for-enspryng-in-nmosd/2480720/Genentech is presenting a range of new data from its neuroscience portfolio at the AAN 2022 Annual Meeting (April 2-7 in Seattle), including
- World’s Thinnest 3D Printed Cornea Implanted in Jerusalemhttps://modernod.com/news/worlds-thinnest-3d-printed-cornea-implanted-in-jerusalem/2480717/Ophthalmologists at Jerusalem’s Shaare Zedek Medical Center (SZMC) have implanted the world's thinnest 3D cornea made from synthetic acrylic material, according to a
- EssilorLuxottica and CooperCompanies Finalize Joint Venturehttps://modernod.com/news/essilorluxottica-and-coopercompanies-finalize-joint-venture/2480705/EssilorLuxottica and CooperCompanies have announced the finalization of their joint venture agreement for SightGlass Vision. This collaboration accelerates the commercialization of novel spectacle lens technologies to expand the myopia management category. SightGlass Vision’s Diffusion
- Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidatehttps://modernod.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies. “Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. &ldquo
- Bunkers That Save Sight? UConn Researchers Take a Close Lookhttps://modernod.com/news/bunkers-that-save-sight-uconn-researchers-take-a-close-look/2480693/Chronically stressing the retina can weaken it and damage our ability to see. But retinal cells have a remarkable ability to wall off damage, a team of neuroscientists led by UConn Health reports in the 1 March issue of PNAS. The w
- UArizona Engineer Leads $1M Project to Fight Vision Losshttps://modernod.com/news/uarizona-engineer-leads-1m-project-to-fight-vision-loss/2480692/Eye infections are common in rural farming communities. A scratch on the cornea caused during agricultural work can get infected and turn into a scar, then an ulcer. These corneal ulcers cause blindness and visual impairment in 4.3 million people worldwide every year, according to data published
- Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis/2480680/Ocuphire Pharma announced that it has completed enrollment in the MIRA-4 trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis (RM) in 23 pediatric subjects. Ocuphire worked closely with Oculos Develop
- Fera Pharmaceuticals Obtains Orphan Drug Designation from the FDA for Naproxcinod for the Treatment of Sickle Cell Diseasehttps://modernod.com/news/nicoxs-partner-fera-pharmaceuticals-obtains-orphan-drug-designation-from-the-us-fda-for-naproxcinod-for-the-treatment-of-sickle-cell-disease/2480673/Nicox SA and Fera Pharmaceuticals announced that the FDA has granted Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an estimated 100,000 Americans. Naproxcinod is a nitr
- Ocumension Obtains Positive Phase 3 Clinical Trial Results for Zerviate in Chinahttps://modernod.com/news/nicoxs-partner-ocumension-obtains-positive-phase-3-clinical-trial-results-for-zerviate-in-china/2480670/Nicox announced positive results in a Chinese phase 3 clinical trial of Zerviate (cetirizine ophthalmic solution), 0.24%, run by its partner, Ocumension Therapeutics.
- Phase 4 Study of Iluvien for DME Shows Statistically Significant Improvements in BCVA, CST, and Treatment Burden at 36 Monthshttps://modernod.com/news/phase-4-paladin-study-with-iluvien-published-in-peer-reviewed-journal-ophthalmology/2480659/Alimera Sciences announced that the 3-year results of the PALADIN study have been published in the peer-reviewed journal Ophthalmology. These study results show that patients with diabetic macular edema (DME) who received a single dose of the sustained release implant Iluv